BioSpace News Archive

IBEX Technologies Inc. reported its financial results for the fiscal year ended July 31, 2020.

Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), today announced that preclinical data from its Gamma Delta T Cell Engager, GADLEN™, platform has been accepted for poster presentation at the Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting,

Acquisition Strengthens Merck’s Oncology Pipeline with VLS-101, an Investigational Antibody-Drug Conjugate to Treat Hematological Malignancies and Solid Tumors

GAAP(1) operating loss was $624 million due to an incremental $1.0 billion pre-tax accrual related to opioid litigation; non-GAAP operating earnings increased 7% to $618 million

Protalix BioTherapeutics, Inc. announced that Dror Bashan, the Company’s President and Chief Executive Officer will present at the H.C. Wainwright 6th Annual Israel Conference on Thursday, November 12, 2020 at 7:30 AM, Eastern Standard Time.

VBL Therapeutics announces that Prof. Dror Harats, M.D., Chief Executive Officer, will provide a corporate overview, in a format of a fireside chat with analyst Swayampakula Ramakanth, Ph.D., at the H.C. Wainwright 6th Annual Israel Conference to be held virtually on November 12th, 2020.

Lexaria Bioscience Corp., a global innovator in oral drug delivery platforms, is pleased to outline its planned strategic initiatives for 2021 with a sharply enhanced focus on solutions related to the regulated pharmaceutical and medical market segments where it believes its patented technology will offer the highest value and utility.

Updated results will be presented from ASPEN-01, the phase 1b study of ALX148 in combination with rituximab in patients with relapsed/refractory non-Hodgkin lymphoma (“NHL”)

Third Quarter TIBSOVO® Net Revenue of $31.7 Million; Company Narrows 2020 TIBSOVO® Net U.S. Revenue Guidance to $113–115 Million

Patient Dosing Underway in Phase 2b clinical trials of IMR-687 in sickle cell disease and beta-thalassemia IMR-687 g rant ed Orphan Drug d esignation from European Commission for sickle cell disease Company to host conference call and live webcast today at 8:30 a.m. ET BOSTON, Nov. 05, 2020